BR112018001431A2 - composição farmacêutica e métodos para prevenção da formação de cccdna do vírus da hepatite b - Google Patents

composição farmacêutica e métodos para prevenção da formação de cccdna do vírus da hepatite b

Info

Publication number
BR112018001431A2
BR112018001431A2 BR112018001431A BR112018001431A BR112018001431A2 BR 112018001431 A2 BR112018001431 A2 BR 112018001431A2 BR 112018001431 A BR112018001431 A BR 112018001431A BR 112018001431 A BR112018001431 A BR 112018001431A BR 112018001431 A2 BR112018001431 A2 BR 112018001431A2
Authority
BR
Brazil
Prior art keywords
hepatitis
virus
formation
pharmaceutical composition
preventing
Prior art date
Application number
BR112018001431A
Other languages
English (en)
Portuguese (pt)
Inventor
Ko Chun-Kyu
Chang Ki-Hwan
Ryu Wang-Shick
Shin Yong-Won
Original Assignee
Mogam Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Inst Biomedical Res filed Critical Mogam Inst Biomedical Res
Publication of BR112018001431A2 publication Critical patent/BR112018001431A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018001431A 2015-07-24 2016-07-22 composição farmacêutica e métodos para prevenção da formação de cccdna do vírus da hepatite b BR112018001431A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150105277A KR101771309B1 (ko) 2015-07-24 2015-07-24 B형 간염 바이러스의 ｃｃｃＤＮＡ 형성 억제용 약학 조성물
PCT/KR2016/008039 WO2017018739A1 (en) 2015-07-24 2016-07-22 Pharmaceutical composition for preventing cccdna formation of hepatitis b virus

Publications (1)

Publication Number Publication Date
BR112018001431A2 true BR112018001431A2 (pt) 2018-09-11

Family

ID=57884746

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001431A BR112018001431A2 (pt) 2015-07-24 2016-07-22 composição farmacêutica e métodos para prevenção da formação de cccdna do vírus da hepatite b

Country Status (6)

Country Link
KR (1) KR101771309B1 (zh)
CN (1) CN108136009A (zh)
BR (1) BR112018001431A2 (zh)
EA (2) EA202092397A3 (zh)
MY (1) MY184876A (zh)
WO (1) WO2017018739A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110859840A (zh) * 2019-11-29 2020-03-06 湖南大学 烟酸在制备慢性乙型肝炎治疗药物中的用途
JP2023538630A (ja) * 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
KR20230166786A (ko) 2022-05-31 2023-12-07 재단법인 아산사회복지재단 소라페닙 및 ddc를 유효성분으로 포함하는 b형 간염유래 간세포암의 예방 또는 치료용 약학적 조성물
CN116804053B (zh) * 2023-08-02 2024-01-26 南方医科大学南方医院 一种抗HBcAg单克隆抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161138A0 (en) * 2001-10-04 2004-08-31 Xtl Biopharmaceuticals Ltd Treatment of hepatitis b virus infection with human monoclonal antibodies
KR100467706B1 (ko) 2002-01-15 2005-01-24 주식회사 녹십자홀딩스 Ｂ형 간염 바이러스의 표면 항원에 대한 인간항체
KR20090056537A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물
CN101642454A (zh) * 2009-07-14 2010-02-10 武汉大学 黄连素在治疗乙肝病毒感染药物中的应用
KR101072895B1 (ko) * 2009-12-24 2011-10-17 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체
CN102631384B (zh) * 2012-04-28 2014-03-12 中国科学院武汉病毒研究所 石榴在制备治疗或预防乙型肝炎病毒感染药物中的应用
JP6431478B2 (ja) * 2012-06-01 2018-11-28 ドレクセル ユニバーシティ Ｂ型肝炎ウイルスのｃｃｃｄｎａの転写の調節
JP2015002723A (ja) * 2013-06-21 2015-01-08 公益財団法人東京都医学総合研究所 Ｈｂｖ特異的人工ｄｎａヌクレアーゼ

Also Published As

Publication number Publication date
KR101771309B1 (ko) 2017-08-24
MY184876A (en) 2021-04-29
EA201890362A1 (ru) 2018-07-31
CN108136009A (zh) 2018-06-08
KR20170011863A (ko) 2017-02-02
WO2017018739A1 (en) 2017-02-02
EA202092397A3 (ru) 2021-06-30
EA202092397A2 (ru) 2021-02-26

Similar Documents

Publication Publication Date Title
MY201148A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
BR112018001431A2 (pt) composição farmacêutica e métodos para prevenção da formação de cccdna do vírus da hepatite b
PH12018500642A1 (en) Anti-garp antibody
MX2019007351A (es) Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas.
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
BR112018017195A2 (pt) terapia de combinação de smc para o tratamento do câncer
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112017028132A2 (pt) métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula
BRPI0622054B8 (pt) composto e composição farmacêutica
BR112016026777A2 (pt) oligômeros e conjugados de oligômeros
BR112017016766A2 (pt) composições farmacêuticas para terapia de combinação
BR112012024661A2 (pt) composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
BR112016026560A2 (pt) Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
SG10201902664RA (en) Combination therapy for treating cancer
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
BR112018007671A2 (pt) terapia de combinação para tratamento de malignidades
BR112021012056A2 (pt) Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit
BR112017013982A2 (pt) fármaco de combinação
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
BR112018071467A2 (pt) método de tratamento ou prevenção de patologias hepáticas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (KR) ; GREEN CROSS CORPORATION (KR)

Owner name: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (KR) ; GRE

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2732 DE 16-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.